- Home
- VYNE vs KZIA Comparison
VYNE vs KZIA Comparison
Compare VYNE & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYNE
- KZIA
- Stock Information
- Founded
- VYNE 2003
- KZIA 1994
- Country
- VYNE United States
- KZIA Australia
- Employees
- VYNE N/A
- KZIA N/A
- Industry
- VYNE Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- VYNE Health Care
- KZIA Health Care
- Exchange
- VYNE Nasdaq
- KZIA Nasdaq
- Market Cap
- VYNE 7.9M
- KZIA 9.0M
- IPO Year
- VYNE 2018
- KZIA 1999
- Fundamental
- Price
- VYNE $0.43
- KZIA $7.12
- Analyst Decision
- VYNE Buy
- KZIA Strong Buy
- Analyst Count
- VYNE 2
- KZIA 3
- Target Price
- VYNE $8.00
- KZIA $16.00
- AVG Volume (30 Days)
- VYNE 3.1M
- KZIA 302.5K
- Earning Date
- VYNE 11-06-2025
- KZIA 11-14-2025
- Dividend Yield
- VYNE N/A
- KZIA N/A
- EPS Growth
- VYNE N/A
- KZIA N/A
- EPS
- VYNE N/A
- KZIA N/A
- Revenue
- VYNE $476,000.00
- KZIA $1,549,158.00
- Revenue This Year
- VYNE N/A
- KZIA N/A
- Revenue Next Year
- VYNE N/A
- KZIA $49.25
- P/E Ratio
- VYNE N/A
- KZIA N/A
- Revenue Growth
- VYNE N/A
- KZIA 248983.08
- 52 Week Low
- VYNE $0.28
- KZIA $2.86
- 52 Week High
- VYNE $4.30
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- VYNE 60.37
- KZIA 44.01
- Support Level
- VYNE $0.32
- KZIA $6.20
- Resistance Level
- VYNE $0.35
- KZIA $8.00
- Average True Range (ATR)
- VYNE 0.02
- KZIA 0.48
- MACD
- VYNE 0.02
- KZIA -0.03
- Stochastic Oscillator
- VYNE 84.88
- KZIA 49.73
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.